Analysts expect Puma Biotechnology Inc (NYSE:PBYI) to report $7.16 million in sales for the current quarter, according to Zacks Investment Research. Three analysts have made estimates for Puma Biotechnology’s earnings, with the lowest sales estimate coming in at $1.59 million and the highest estimate coming in at $15.00 million. The company is scheduled to announce its next quarterly earnings report on Wednesday, November 8th.

On average, analysts expect that Puma Biotechnology will report full year sales of $7.16 million for the current fiscal year, with estimates ranging from $7.96 million to $45.00 million. For the next fiscal year, analysts anticipate that the company will report sales of $284.91 million per share, with estimates ranging from $115.74 million to $502.50 million. Zacks’ sales calculations are a mean average based on a survey of research analysts that follow Puma Biotechnology.

Puma Biotechnology (NYSE:PBYI) last posted its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($2.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.32) by $0.78.

A number of equities research analysts have commented on the stock. Citigroup Inc. raised shares of Puma Biotechnology to a “buy” rating and set a $105.00 price objective on the stock in a report on Sunday, May 28th. Royal Bank Of Canada increased their price objective on shares of Puma Biotechnology from $40.00 to $60.00 and gave the stock a “sector perform” rating in a report on Thursday, May 25th. J P Morgan Chase & Co reissued a “buy” rating on shares of Puma Biotechnology in a report on Tuesday, July 18th. Stifel Nicolaus reissued a “buy” rating and set a $118.00 price objective (up previously from $105.00) on shares of Puma Biotechnology in a report on Tuesday, July 18th. Finally, Zacks Investment Research lowered shares of Puma Biotechnology from a “buy” rating to a “hold” rating in a report on Wednesday, June 7th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have issued a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $109.56.

TRADEMARK VIOLATION WARNING: This piece of content was first posted by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another website, it was illegally stolen and reposted in violation of United States & international copyright law. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2017/08/22/7-16-million-in-sales-expected-for-puma-biotechnology-inc-pbyi-this-quarter.html.

In other Puma Biotechnology news, insider Alan H. Auerbach sold 13,175 shares of the company’s stock in a transaction dated Thursday, July 20th. The shares were sold at an average price of $94.73, for a total transaction of $1,248,067.75. Following the transaction, the insider now directly owns 4,170,623 shares in the company, valued at approximately $395,083,116.79. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP Richard Paul Bryce sold 1,998 shares of the company’s stock in a transaction dated Thursday, July 20th. The shares were sold at an average price of $94.48, for a total transaction of $188,771.04. Following the transaction, the senior vice president now owns 27,246 shares in the company, valued at $2,574,202.08. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 2,010,261 shares of company stock worth $159,425,452. Corporate insiders own 22.70% of the company’s stock.

Several hedge funds have recently made changes to their positions in PBYI. Janus Henderson Group PLC purchased a new stake in shares of Puma Biotechnology during the second quarter worth $162,302,000. Camber Capital Management LLC purchased a new stake in shares of Puma Biotechnology during the first quarter worth $24,180,000. Franklin Resources Inc. purchased a new stake in shares of Puma Biotechnology during the second quarter worth $50,134,000. Redmile Group LLC increased its stake in shares of Puma Biotechnology by 33.7% in the first quarter. Redmile Group LLC now owns 1,725,414 shares of the biopharmaceutical company’s stock worth $64,185,000 after buying an additional 435,274 shares in the last quarter. Finally, Emerald Advisers Inc. PA purchased a new stake in shares of Puma Biotechnology during the first quarter worth $14,110,000. Institutional investors and hedge funds own 80.98% of the company’s stock.

Shares of Puma Biotechnology (PBYI) opened at 80.60 on Tuesday. Puma Biotechnology has a 52-week low of $28.35 and a 52-week high of $98.85. The company’s market capitalization is $3.00 billion. The firm’s 50 day moving average is $87.47 and its 200-day moving average is $58.78.

About Puma Biotechnology

Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.

Get a free copy of the Zacks research report on Puma Biotechnology (PBYI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Puma Biotechnology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology Inc and related companies with MarketBeat.com's FREE daily email newsletter.